Caricamento...
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
AIM: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective. METHODS: A semi-Markov model compared secukinumab with adalimumab, adalimumab biosimilar, certolizumab pego...
Salvato in:
| Pubblicato in: | Clinicoecon Outcomes Res |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6386207/ https://ncbi.nlm.nih.gov/pubmed/30858713 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S192235 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|